Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Naurex
Biotech
Allergan’s NMDA drug rapastinel fails phase 3 depression studies
Rapastinel, the depression drug that Allergan picked up in its $560 million Naurex acquisition, missed its primary endpoint in three pivotal trials.
Amirah Al Idrus
Mar 7, 2019 9:02am
Aptinyx seeks $80M IPO to push NMDA drug platform
May 24, 2018 9:45am
Allergan acquires NMDA depression drug from Aptinyx collab
May 22, 2018 10:30am
Aptinyx bags $70M to fund multidrug CNS trial strategy
Dec 18, 2017 7:30am
Naurex vets reprise blockbuster NMDA R&D role with $65M startup round
May 10, 2016 1:30am
